The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo.
about
Ohmyungsamycins promote antimicrobial responses through autophagy activation via AMP-activated protein kinase pathway.In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.Structure and Functional Properties of the Active Form of the Proteolytic Complex, ClpP1P2, from Mycobacterium tuberculosis.Crystal Structure and Biochemical Characterization of a Mycobacterium smegmatis AAA-Type Nucleoside Triphosphatase Phosphohydrolase (Msm0858).Bioautography with TLC-MS/NMR for Rapid Discovery of Anti-tuberculosis Lead Compounds from Natural Sources.Missense Mutations in the Unfoldase ClpC1 of the Caseinolytic Protease Complex Are Associated with Pyrazinamide Resistance in Mycobacterium tuberculosisDiscovery of novel drug targets and their functions using phenotypic screening of natural products.Natural products as probes in pharmaceutical research.Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.Functional Diversity of AAA+ Protease Complexes in Bacillus subtilis.Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.Advances in identification and validation of protein targets of natural products without chemical modification.Bacterial proteases, untapped antimicrobial drug targets.Targeting Phenotypically Tolerant Mycobacterium tuberculosis.AAA+ Machines of Protein Destruction in Mycobacteria.Discovery and characterization of the tuberculosis drug lead ecumicin.Crystal structures reveal N-terminal Domain of Arabidopsis thaliana ClpD to be highly divergent from that of ClpC1.Mutation in clpC1 encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in Mycobacterium tuberculosis.Regulatory coiled-coil domains promote head-to-head assemblies of AAA+ chaperones essential for tunable activity control.Actinomycetes: still a source of novel antibiotics.Antituberculotic activity of actinobacteria isolated from the rare habitats.New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.Improvement of the productivity of ecumicin, a novel anti-tuberculosis agent, from new Nonomuraea sp. MJM5123.AntiTbPdb: a knowledgebase of anti-tubercular peptides.Targeting the Proteostasis Network for Mycobacterial Drug Discovery.The antibiotic cyclomarin blocks arginine-phosphate-induced millisecond dynamics in the N-terminal domain of ClpC1 from Mycobacterium tuberculosis.Computer-assisted 1 H NMR analysis of the anti-tuberculosis drug lead ecumicin.Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains.Prediction of Antitubercular Peptides From Sequence Information Using Ensemble Classifier and Hybrid Features
P2860
Q33794131-DF19B0A3-2A08-40B5-A9FC-491E6B629ECDQ33912749-A795C7BA-1430-4DD7-A643-9DA35BFB60CCQ36755029-9A95CA91-E77A-4D5D-AC1B-B3592E868F43Q36878469-9A475AC4-6D14-4398-8D3F-A4CADB45E50FQ37130906-8AEB4E3C-C50B-477E-BC1C-5EB15312F897Q37612920-ADAA41BD-4955-4B5E-B1AA-FA78CFD1FC35Q38585751-923D9FD8-D0F3-4BBA-9D5A-2DA95F044D22Q38599715-924A9686-B773-4CE4-8B20-F821B5B56E97Q38639542-7D9733C1-A89C-4970-99B2-E9B6E0964604Q38658749-EA77DD96-9BD0-4CB5-B494-06F08506182CQ38662313-97E9C10E-ED0F-466D-B10D-AFF45FAAABDEQ38768845-DFB07E6E-25DC-4A82-B686-05867595545EQ39023951-E1217862-4208-4CE2-9942-DA2FD412D66AQ39149038-5F1D0E90-F640-4F6C-BBFB-DBCF32D12A5BQ41050594-E8BE202C-6FCD-44B0-B777-0142427A7F81Q41809992-E11E0A99-B406-45E5-B6C4-61FED2E3BDBBQ42118621-1BCF4096-AF59-43F5-A490-501C2BAD98B2Q42320288-0950EBC9-EB84-46DA-9D7D-291F5422AFDCQ45344399-8471CFD3-EE58-4BA4-B02A-33A3C3BA9250Q46319269-DBFDEB64-C2FF-4306-A8C7-836D1B6E07DDQ46337276-2CC904BA-1B8F-47E8-9A32-E6C57BABB87FQ47594312-CFA45A2D-86E9-46F7-A417-3C6369001CFFQ51614255-92C07CC3-07AD-4DF0-BE49-80F0F2893DDAQ52567295-18007BE5-6084-4695-A095-03A913F8F1EDQ52692190-849F4CA8-E8F3-4A62-A0EE-0D29AF5182B3Q53697056-78F60A6F-9409-4EED-AB3B-2DD2621B2B5DQ54857901-32BAFC04-B03D-483E-8C95-E9E24DE867EAQ55091455-EF3C4AC0-6FF7-42A4-B6BD-383773DF8FC3Q57319273-3EA9A233-F085-40FE-8839-206A502AA505
P2860
The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The cyclic peptide ecumicin ta ...... acterium tuberculosis in vivo.
@ast
The cyclic peptide ecumicin ta ...... acterium tuberculosis in vivo.
@en
type
label
The cyclic peptide ecumicin ta ...... acterium tuberculosis in vivo.
@ast
The cyclic peptide ecumicin ta ...... acterium tuberculosis in vivo.
@en
prefLabel
The cyclic peptide ecumicin ta ...... acterium tuberculosis in vivo.
@ast
The cyclic peptide ecumicin ta ...... acterium tuberculosis in vivo.
@en
P2093
P2860
P50
P356
P1476
The cyclic peptide ecumicin ta ...... acterium tuberculosis in vivo.
@en
P2093
Alfred L Goldberg
James B McAlpine
Jeffrey R Anderson
Jin-Yong Kim
Jong-Woo Kim
Joo-Won Suh
Olga Kandror
Sanghyun Cho
Seung-Hwan Yang
P2860
P304
P356
10.1128/AAC.04054-14
P407
P577
2014-11-24T00:00:00Z